ERBB2 and cancer: Collectively, these results indicate that HER2 downregulation in cancer cells requires direct interaction of the trastuzumab Fab region with the HER2 antigen on cancer cells and the Fc region with FcγRs on immune cells, which brings cancer cells and immune cells in proximity for activating the immune effector function.